Literature DB >> 27785922

Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.

Kun Hu1, Juan Zhang2, Min Yu3, Chang'e Xiong4.   

Abstract

AIM: We investigated whether MAPK-interacting kinase (Mnk) inhibition sensitizes anaplastic thyroid cancer (ATC) cellular response to chemotherapy. MATERIALS &
METHODS: In vitro and in vivo methods were used to examine the combinatory effects of cisplatin with Mnk inhibition and its underlying mechanism.
RESULTS: Mnk inhibition by pharmacological or genetic approaches inhibits proliferation and induces apoptosis of ATC cells and enhances the effects of cisplatin in in vitro and in vivo. Mechanistically, cisplatin increases eIF4E phosphorylation in a dose- and time-dependent manner in ATC cells. Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation.
CONCLUSION: Targeting Mnk-eIF4E pathway provides a therapeutic strategy by sensitizing ATC response to chemotherapeutic drug.

Entities:  

Keywords:  Mnk; chemotherapy; eIF4E; thyroid cancer

Mesh:

Substances:

Year:  2016        PMID: 27785922     DOI: 10.2217/fon-2016-0320

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.

Authors:  Ahmed Katsha; Lihong Wang; Janet Arras; Omar M Omar; Jeffrey Ecsedy; Abbes Belkhiri; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

Review 2.  Phosphorylation of the mRNA cap-binding protein eIF4E and cancer.

Authors:  Xiaotong Yang; Wu Zhong; Ruifeng Cao
Journal:  Cell Signal       Date:  2020-06-11       Impact factor: 4.315

Review 3.  Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.

Authors:  Celia Pinto-Díez; Raquel Ferreras-Martín; Rebeca Carrión-Marchante; Víctor M González; María Elena Martín
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.